Pediatric Dosing and Body Size in Biotherapeutics
Open Access
- 16 December 2010
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 2 (4), 389-418
- https://doi.org/10.3390/pharmaceutics2040389
Abstract
Although pediatric doses for biotherapeutics are often based on patients' body weight (mg/kg) or body surface area (mg/m2), linear body size dose adjustment is highly empirical. Growth and maturity are also important factors that affect the absorption, distribution, metabolism and excretion (ADME) of biologics in pediatrics. The complexity of the factors involved in pediatric pharmacokinetics lends to the reconsideration of body size based dose adjustment. A proper dosing adjustment for pediatrics should also provide less intersubject variability in the pharmacokinetics and/or pharmacodynamics of the product compared with no dose adjustment. Biological proteins and peptides generally share the same pharmacokinetic principle with small molecules, but the underlying mechanism can be very different. Here, pediatric and adult pharmacokinetic parameters are compared and summarized for selected biotherapeutics. The effect of body size on the pediatric pharmacokinetics for these biological products is discussed in the current review.This publication has 122 references indexed in Scilit:
- A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: A Children's Oncology Group reportPediatric Blood & Cancer, 2009
- Infliximab Treatment of Intravenous Immunoglobulin–Resistant Kawasaki DiseaseThe Journal of Pediatrics, 2008
- Overview of the human pharmacokinetics of recombinant activated factor VIIBritish Journal of Clinical Pharmacology, 2007
- Population pharmacokinetics–pharmacodynamics of alemtuzumab (Campath®) in patients with chronic lymphocytic leukaemia and its link to treatment responseBritish Journal of Clinical Pharmacology, 2007
- Pharmacokinetics, Pharmacodynamics and Drug Interaction Potential of EnfuvirtideClinical Pharmacokinetics, 2005
- Pharmacokinetics of Gemtuzumab Ozogamicin, an Antibody‐Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First RelapseThe Journal of Clinical Pharmacology, 2001
- Pharmacokinetic Studies with Recombinant CytokinesClinical Pharmacokinetics, 1997
- Pharmacokinetics and effectiveness of recombinant erythropoietin administered to preterm infants by continuous infusion in total parenteral nutrition solutionThe Journal of Pediatrics, 1996
- Problems of Delivery of Monoclonal AntibodiesClinical Pharmacokinetics, 1995
- Atrial Natriuretic PeptideClinical Pharmacokinetics, 1993